Company Profile

Algynomics Inc
Profile last edited on: 3/11/19      CAGE: 4GXR7      UEI:

Business Identifier: Pain diagnostics and management
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

208 North Columbia Street
Chapel Hill, NC 27514
   (919) 261-7886
Location: Single
Congr. District: 04
County: Orange

Public Profile

Acquired by Proove Biosciences in May 2016, Algynomics Inc is focused on development of personalized pain therapies and new pharmacological treatments for chronic pain conditions. The Algynomics platform and its patient cohorts provide researchers with prospective data to identify individuals at increased risk for the development of chronic pain, allowing targeted preventive efforts, enhanced patient stratification in clinical trials to identify treatment responders, produce more sensitive inclusion/exclusion criteria for trial enrollment, and development of algorithms to tailor treatment for pain, enhancing outcomes and reducing adverse effects. Algynomics developed the Translational Pain Genetics Consortium (TPGC) to improve the effectiveness and efficiency of applied and fundamental pain research through exclusive availability of cross-validated unique cohorts of pain patient supported by Algynomics experience, expertise and state of the art analytical tools.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $656,967
Project Title: Development of a Novel Class for Opioid Drugs

Key People / Management

  William Maixner -- President

  Luda Diatchenko -- CSO

  Roger B Fillingim -- Vice President of Clinical Research Services

  Richard H Gracely -- Vice President of Device Development

  Alex Selptsov -- Vice President of Corporate Strategy